All News

Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering

Intercell, an Austrian biotechnology company, has received a $1 million milestone payment from Merck for progress in the development of a bacterial vaccine candidate.

Nanonucleant, a spin-out of Imperial College London, is seeking angel financing to move ahead with a glass grain-based technology that aids in crystallising proteins for study as drug targets.

US biotechnology firm DOR BioPharma plans to build a bigger force in gastro-intestinal medicines by buying Copenhagen-based Gastrotech Pharma, a spin-out of Gothenburg University in Sweden.

With an estimated 400 million people at risk for developing dementia, a natural remedy would be a welcome answer. That's the approach one British company is taking.

"Basic research may seem very expensive. I am a well-paid scientist. My hourly wage is equal to that of a plumber..." Albert Szent-Györgyi, Nobel-winning chemist

The University of Cambridge is considering whether to make more cash available to invest in campus spin-off companies. And whatever decision it makes will come in for criticism…

Shares in Oxford BioMedica, an Oxford University spin-out, fell 8.3 percent on news that the company was seeking up to £30 million to fund the Phase III trial of its a TroVax cancer immunotherapy product.

Reports of incubators' demise were premature

After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.

Not all nanotechnology is hype. Carbon nanotubes are already inside a product near you.

The Cambridge-based company a.gain medical says it has invented the world's first urethral sensor for women – and is looking for further investment.

A team of European researchers is applying a technology used to measure airflow over aircraft wings to improve human heart implants.

Britain's privatised defence lab ties up with 7 universities, in a strategy to do more with fewer partners.

UK-based AMDG's monitor for early detection of heart conditions particularly associated with diabetics is already selling in Germany. Now the company is now looking for support to enter into the US market.